Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein.
about
Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunitiesEnhanced brain disposition and effects of Δ9-tetrahydrocannabinol in P-glycoprotein and breast cancer resistance protein knockout miceA multi-system approach assessing the interaction of anticonvulsants with P-gpRole of Human Breast Cancer Related Protein versus P-Glycoprotein as an Efflux Transporter for Benzylpenicillin: Potential Importance at the Blood-Brain BarrierNeuroinflammation activates Mdr1b efflux transport through NFkappaB: promoter analysis in BBB endotheliaP-glycoprotein inhibition increases the brain distribution and antidepressant-like activity of escitalopram in rodentsChallenges of using in vitro data for modeling P-glycoprotein efflux in the blood-brain barrier.In vitro antineoplastic effects of brivaracetam and lacosamide on human glioma cells.Drug-Resistant Epilepsy: Multiple Hypotheses, Few AnswersRegulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrierDifferences in the expression of endogenous efflux transporters in MDR1-transfected versus wildtype cell lines affect P-glycoprotein mediated drug transport.Drug resistance in cortical and hippocampal slices from resected tissue of epilepsy patients: no significant impact of p-glycoprotein and multidrug resistance-associated proteinsCYP2C9, CYP2C19, and ABCB1 genotype and hospitalization for phenytoin toxicityFactors Governing P-Glycoprotein-Mediated Drug-Drug Interactions at the Blood-Brain Barrier Measured with Positron Emission Tomography.Brain tumor-related epilepsy.Inhibition of P-glycoprotein enhances transport of imipramine across the blood-brain barrier: microdialysis studies in conscious freely moving rats.Blood-brain barrier dysfunction in epileptogenesis of the temporal lobeImproving the prediction of the brain disposition for orally administered drugs using BDDCS.Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy.Imaging of P-glycoprotein function and expression to elucidate mechanisms of pharmacoresistance in epilepsy.A novel positron emission tomography imaging protocol identifies seizure-induced regional overactivity of P-glycoprotein at the blood-brain barrierThe emerging importance of transporter proteins in the psychopharmacological treatment of the pregnant patient.Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy.The antiepileptic drug mephobarbital is not transported by P-glycoprotein or multidrug resistance protein 1 at the blood-brain barrier: a positron emission tomography study.Overlapping substrate and inhibitor specificity of human and murine ABCG2.The blood-brain barrier in migraine treatment.Nanotechnology for delivery of drugs to the brain for epilepsy.Epilepsy pharmacogenetics.Drug transporters: gatekeepers controlling access of xenobiotics to the cellular interior.Identification of interspecies difference in hepatobiliary transporters to improve extrapolation of human biliary secretion.ABC transporters in drug-refractory epilepsy: limited clinical significance of pharmacogenetics?Transporter hypothesis of drug-resistant epilepsy: challenges for pharmacogenetic approaches.Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?Fexofenadine hydrochloride in the treatment of allergic disease: a reviewFactors influencing the use and interpretation of animal models in the development of parenteral drug delivery systemsPharmacogenomics and epilepsy: the road ahead.Species differences in drug transporters and implications for translating preclinical findings to humans.Mechanisms of drug resistance in epilepsy: relevance for antiepileptic drug discovery.Levetiracetam compared with valproic acid for the prevention of postoperative seizures after supratentorial tumor surgery: a retrospective chart review.Development of individualized medicine for epilepsy based on genetic information.
P2860
Q26828930-0F9D6CCE-6D45-492E-B62B-FFA333145625Q28482464-6C32B25D-9E7E-4019-9689-78E685AEB788Q28533527-AB7B9ED3-CD60-4297-92F3-ECD6263E74FBQ28550262-B4FCF3FC-EB6C-4780-A539-83EB7181E2C6Q28578682-E7E946A3-8183-49CB-BA1D-D4D55F1F5E00Q30544869-CE48DFD8-D6A3-49A7-B0A3-6FA83716036FQ30651426-A119580E-AD2D-4C91-9FE3-1C54F3341AB1Q33768138-65DC45A7-6408-4A19-BF1D-3C9CCFBB89A8Q33875271-704A78E0-1237-4D8C-9C8A-6726C17723F1Q33900889-A53583A1-E5CB-4324-880A-9F773A88447AQ34124847-A372F414-4649-4998-BC22-65637B063183Q35094603-B883BE61-2F17-4074-94BC-56ED01608F2DQ35117277-32D01C47-40F2-4454-9ECA-87D3F0448E80Q36049576-870578F5-E0F9-4E49-AE44-45BA4F3A165AQ36067319-4E209F6D-B25D-424E-9357-594738F095FAQ36159042-A0EE7927-2320-4779-ABE6-482ADF3D55B8Q36168832-32FDC6FB-800C-4824-9F20-4D406E165B8BQ36394062-74F5F761-D3FF-4B96-A9DC-26C8870A7B56Q36603317-AF2AF05E-2643-470C-9822-FD06FC2D6E62Q36947636-27E80001-1CD3-4536-9C9C-49CF88DEC10DQ36955931-A6D1F1C9-54EA-47C9-9462-8922B241B5D2Q37024001-ECB76D9C-6317-40EF-9FC3-D59A63EA5885Q37080236-13899A2A-4DD3-4AC2-957F-588BDFBD6333Q37185659-7F7C1FB9-C13B-4F1D-A354-EF1631783E00Q37193073-94A8E652-EF8F-4EAA-8310-4DF297B4925BQ37252452-7078365C-E536-4105-907A-4BD256537488Q37426991-E21EBCEF-739B-458E-BF9D-61DA43E3CB9DQ37486720-02732B65-BB44-409B-B244-C8DE14052449Q37514340-000C55AE-B55D-4F90-B253-C92B1B1C4F70Q37554392-B8E04638-14F2-4873-ACD4-E419B98EC6F9Q37658265-1F6DE01F-00E5-4590-AA1B-214BFAB17697Q37806763-7CF32207-30F9-415B-9DC5-4D23EAF4D6CEQ37853578-A29126AA-DF38-40A7-8B01-BDD1D0F2D3DDQ37857671-B9522410-997E-434A-A709-F8BC196ED031Q37942472-2CB96AE8-4489-498E-896A-7AE6A8243AEBQ37946957-997E39B7-AAB7-4C47-91DA-8AC3432A81B6Q38068912-0F0C4D63-A2C0-4516-9A66-D50651DF675DQ38088316-2F1D8F20-46BC-4360-A261-7C60EDFE330FQ38127128-B8AF6126-82EB-4B0D-BF0B-E93ABD8FA0D3Q38178326-DD17D8F4-3D18-42AE-A805-7022CAFCBDB8
P2860
Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Differences in the transport o ...... uman and mouse P-glycoprotein.
@en
type
label
Differences in the transport o ...... uman and mouse P-glycoprotein.
@en
prefLabel
Differences in the transport o ...... uman and mouse P-glycoprotein.
@en
P2093
P1433
P1476
Differences in the transport o ...... uman and mouse P-glycoprotein.
@en
P2093
Alexandra M Gastens
Maren Fedrowitz
Steffen Baltes
Volkhard Kaever
Wolfgang Löscher
P304
P356
10.1016/J.NEUROPHARM.2006.07.038
P577
2006-10-10T00:00:00Z